# Thymulin: The Zinc-Dependent Thymic Nonapeptide — Research Source > Thymulin is a 9-amino-acid thymic hormone that requires zinc for biological activity. Research record on T-cell differentiation, immunosenescence, and analgesic properties — peer-reviewed and cited. ## Thymulin (Serum Thymic Factor): Background and Discovery Thymulin — historically called serum thymic factor, or FTS from the French *facteur thymique sérique* — was isolated and characterized in the early 1970s by Bach and Dardenne. It is a nonapeptide: nine amino acids in the sequence pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn. Molecular weight: 858.86 Da. CAS number: 63958-90-7. The defining feature is zinc dependency. Thymulin is biologically inactive without a bound zinc ion. The zinc-free form — apothymulin — circulates in serum but produces no immunological effect. Only the Zn-thymulin complex binds the thymulin receptor on T-lymphocyte precursors.[1] Production is exclusive to thymic epithelial cells. No other tissue has been identified as a source.[22] Serum thymulin follows a circadian rhythm, with peak levels measured at approximately 1:00 a.m. in rodent models.[23, 24] The serum thymic factor literature spans more than four decades and multiple research groups — primarily the Bach/Dardenne group (France/Lebanon), the Reggiani/Goya group (Argentina), and the Novoselova/Lunin group (Russia). The findings are consistent: T-cell differentiation, cytokine modulation, and an age-related decline tied to both thymic involution and zinc insufficiency. ## What Is Thymulin? Thymulin is an endogenous nonapeptide hormone produced exclusively by thymic epithelial cells. It was originally described as serum thymic factor (FTS) in the 1970s. Biological activity depends on a 1:1 molar complex with zinc — the zinc-free apothymulin is immunologically inert.[1] As of the peer-reviewed literature, Thymulin has no FDA-approved therapeutic indication. It is studied as a research compound. ## What Is Thymulin Used For in Research? Across the published record, Thymulin has been studied for: - **T-cell differentiation**: Inducing surface expression of T-cell markers (Thy-1, Lyt-1, Lyt-2) on immature thymocytes and bone marrow precursor cells[4] - **Immune modulation**: Suppressing pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6, IFN-gamma) while upregulating anti-inflammatory IL-10[12] - **Analgesic activity**: Dose-dependent reduction of thermal hyperalgesia and inflammatory pain in rodent models[14, 15] - **Neuroprotection**: Inhibition of NF-kappaB nuclear translocation in hippocampal astrocytes[17] - **Immunosenescence research**: Characterizing and partially reversing age-related thymic decline via zinc repletion and gene therapy approaches[7, 21] No approved human therapeutic indication exists. ## Where Is Thymulin Produced? Thymulin is produced by two distinct epithelial cell populations within the thymus gland.[22] Serum levels are detectable only when the peptide is zinc-bound — the zinc-free form is immunologically silent. Growth hormone, prolactin, and thyroid hormones stimulate thymulin production from thymic epithelium; thymulin reciprocally regulates anterior pituitary ACTH release, establishing a bidirectional neuroendocrine-immune axis.[24] Production peaks in children aged 5–10 years. Measurable decline begins after puberty. By age 36, mean serum titres in a cross-sectional cohort of 93 healthy subjects dropped from a peak of 4.77 to 0.66.[6] ## The Research Record at a Glance The thymulin peptide literature includes: - **Zinc dependency** — biochemically characterized 1982 (Dardenne et al., PNAS)[1]; three-dimensional zinc-dependent epitope confirmed 1985[3] - **T-cell differentiation** — synthetic FTS induced T-cell surface markers on human bone marrow precursor cells in vitro (Incefy et al., 1980)[4] - **Human zinc deficiency** — serum thymulin activity restored by oral zinc supplementation in zinc-deficient human subjects (Prasad et al., 1988, Journal of Clinical Investigation)[5] - **Age-related decline** — quantitative lifespan trajectory documented in 93 healthy humans across 80 years (Consolini et al., 2000)[6] - **Cytokine suppression** — 15 µg/100g i.p. prevented plasma accumulation of five pro-inflammatory cytokines in LPS-challenged mice (Lunin et al., 2008)[12] - **Inflammatory pain** — reduced thermal hyperalgesia and spinal microglial activation in CFA rat models (Nasseri et al., 2019)[14] - **Gene therapy** — single intratracheal nanoparticle dose reversed key pathology of experimental allergic asthma within 20 days (Science Advances, 2020)[26] ## References [1] Dardenne M, Pleau JM, Nabarra B, et al. Contribution of zinc and other metals to the biological activity of the serum thymic factor. Proc Natl Acad Sci USA. 1982;79(17):5370-5373. https://pubmed.ncbi.nlm.nih.gov/6957870/ [3] Dardenne M, Savino W, Berrih S, Bach JF. A zinc-dependent epitope on the molecule of thymulin, a thymic hormone. Proc Natl Acad Sci USA. 1985;82(20):7035-7038. https://pubmed.ncbi.nlm.nih.gov/2413455/ [4] Incefy GS, et al. Induction of differentiation in human marrow T cell precursors by the synthetic serum thymic factor, FTS. Clin Exp Immunol. 1980;40(3):396-406. https://pubmed.ncbi.nlm.nih.gov/6969145/ [5] Prasad AS, et al. Serum thymulin in human zinc deficiency. J Clin Invest. 1988;82(4):1202-1210. https://pmc.ncbi.nlm.nih.gov/articles/PMC442670/ [6] Consolini R, et al. Distribution of age-related thymulin titres in normal subjects through the course of life. Clin Exp Immunol. 2000;121(3):444-447. https://pmc.ncbi.nlm.nih.gov/articles/PMC1905732/ [7] Mocchegiani E, et al. Reversibility of the thymic involution by zinc supplementation in old mice. Int J Immunopharmacol. 1995;17(9):703-718. https://pubmed.ncbi.nlm.nih.gov/8582782/ [12] Lunin SM, et al. Thymulin prevents overproduction of pro-inflammatory cytokines. Immunol Invest. 2008;37(8):858-873. https://pubmed.ncbi.nlm.nih.gov/18991101/ [14] Nasseri B, et al. Thymulin treatment attenuates inflammatory pain. Int Immunopharmacol. 2019;70:89-97. https://pubmed.ncbi.nlm.nih.gov/30851702/ [15] Safieh-Garabedian B, et al. Potent analgesic and anti-inflammatory actions of a novel thymulin-related peptide. Br J Pharmacol. 2002;136(3):421-428. https://pmc.ncbi.nlm.nih.gov/articles/PMC1573422/ [17] Haddad JJ, Hanbali LH. Anti-Inflammatory Activity of Thymulin Peptide is NF-kappaB-Dependent. Am J Med Biol Res. 2013;1(2):35-44. https://pubs.sciepub.com/ajmbr/1/2/2/ [21] Reggiani PC, et al. Thymulin-Based Gene Therapy and Pituitary Function in Animal Models of Aging. Neuroimmunomodulation. 2011;18(5):279-285. https://pmc.ncbi.nlm.nih.gov/articles/PMC3221262/ [22] Reggiani PC, et al. Physiology and therapeutic potential of the thymic peptide thymulin. Curr Pharm Des. 2014;20(29):4690-4696. https://pubmed.ncbi.nlm.nih.gov/24588820/ [23] Hadley AJ, et al. Thymulin stimulates corticotrophin release in the rat anterior pituitary gland. Neuroimmunomodulation. 1997;4(2):62-69. https://pubmed.ncbi.nlm.nih.gov/9483196/ [24] Reggiani PC, et al. The Thymus-Neuroendocrine Axis. Ann N Y Acad Sci. 2009;1153:98-106. https://pmc.ncbi.nlm.nih.gov/articles/PMC2688715/ [26] Nanoparticle-based thymulin gene therapy reverses key pathology of experimental allergic asthma. Sci Adv. 2020;6(25):eaay7973. https://pmc.ncbi.nlm.nih.gov/articles/PMC7286682/ --- The peer-reviewed thymulin record, cited at the source — not a clinic, not a vendor.